Nativis Voyager device emitting a soft glow, symbolizing hope and healing for glioblastoma

Hope for Brain Cancer: A New Device Offers a Ray of Light for Recurrent Glioblastoma

Mira Elwood in Health & Wellness July 2025 • 4 min read.

"An early study reveals the Nativis Voyager® device shows promise in treating recurrent glioblastoma, offering a non-invasive approach to battling this aggressive cancer."

Glioblastoma (GBM) is a formidable foe, recognized as one of the most aggressive forms of cancer that originates in the brain. Its relentless nature and the limited success of conventional treatments have long presented a significant challenge to both patients and the medical community. Standard treatments, including surgery, radiation, and chemotherapy, often fall short, especially when the cancer recurs.

But amidst this landscape of adversity, a new horizon of hope has emerged. The Nativis Voyager® device, an innovative and non-invasive technology, is now offering a potential new avenue for treatment. Recent studies are showing that this device could be a safe and feasible option for those battling recurrent glioblastoma (rGBM).

This article explores the promise of the Nativis Voyager® device, delving into its mechanisms, the outcomes of early feasibility studies, and its potential role in reshaping the future of brain cancer treatment. This approach aims to respect the science while presenting it in an accessible way, especially for those seeking practical insights.

How Does the Nativis Voyager® Device Work?

Nativis Voyager device emitting a soft glow, symbolizing hope and healing for glioblastoma

The Nativis Voyager® device introduces a novel approach to cancer treatment. Unlike traditional methods that rely on surgery, radiation, or systemic drugs, Voyager uses ultra-low radio frequency energy (ulRFE®) to target tumors. This innovative device is designed to be non-invasive, non-thermal, and non-ionizing, setting it apart from conventional cancer therapies.

The device works by delivering ulRFE through an electromagnetic coil worn on the head. This energy is believed to penetrate tissues and interact with specific biological functions within cells. The Voyager system comprises three key components: a battery-operated controller, the electromagnetic coil, and a battery charger. Here's a breakdown of the system's key components:

Battery-Operated Controller: Functions as the central processing unit, managing and delivering the ultra-low radio frequency energy.
Electromagnetic Coil: This is worn externally on the head, much like a crown. It delivers the ulRFE to the targeted tissues.
Battery Charger: Ensures the device remains operational, providing a continuous supply of energy for ongoing treatment.

The ulRFE cognate, known as A1A, is thought to influence the distribution of charge within the β-tubulin monomer. This action leads to a change that strengthens bonds between monomers and dimers, potentially disrupting cell division at metaphase. The Voyager device is designed for ease of use, allowing patients to continue with their daily activities without significant disruption.

Looking Ahead: The Future of Voyager in Cancer Therapy

The Nativis Voyager® device represents a significant leap forward in the treatment of recurrent glioblastoma, offering a non-invasive alternative that has demonstrated safety and feasibility in early studies. As research continues, the Voyager holds potential not only for brain cancer but also for other types of tumors and non-oncological applications. The future may see Voyager integrated into multi-modality treatment approaches, utilizing a combination of cognates and drug therapies to enhance effectiveness and patient outcomes.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is the Nativis Voyager® device and how does it work in treating recurrent glioblastoma (rGBM)?

The Nativis Voyager® device is a non-invasive treatment option for recurrent glioblastoma (rGBM). It uses ultra-low radio frequency energy (ulRFE®) delivered via an electromagnetic coil worn on the head. This energy is designed to target tumors by influencing specific biological functions within the cells. The ulRFE cognate, A1A, is believed to affect the charge distribution within the β-tubulin monomer, potentially disrupting cell division at metaphase. The system includes a battery-operated controller, the electromagnetic coil, and a battery charger, ensuring ease of use for patients.

How does the Nativis Voyager® device differ from traditional glioblastoma treatments?

Unlike standard treatments like surgery, radiation, and chemotherapy, the Nativis Voyager® device offers a non-invasive approach. It does not rely on physically removing the tumor or using systemic drugs that can affect the entire body. Instead, it uses ultra-low radio frequency energy (ulRFE®) to target the tumor directly, aiming to disrupt cancer cell division without the side effects often associated with traditional methods. This method offers a more patient-friendly approach, allowing individuals to continue their daily activities during treatment.

What are the key components of the Nativis Voyager® device?

The Nativis Voyager® device consists of three main components: a battery-operated controller, an electromagnetic coil, and a battery charger. The controller manages and delivers the ultra-low radio frequency energy (ulRFE®). The electromagnetic coil is worn on the head to deliver the ulRFE to the targeted tissues. The battery charger ensures the device has a continuous supply of energy for the ongoing treatment.

What is the role of ulRFE® and A1A in the function of the Nativis Voyager® device?

The ultra-low radio frequency energy (ulRFE®) is the core technology of the Nativis Voyager® device. The ulRFE® is delivered via an electromagnetic coil to target tumors. Within the tumor cells, ulRFE® interacts with the cognate A1A, which is believed to influence the distribution of charge within the β-tubulin monomer. This action is thought to strengthen the bonds between monomers and dimers, potentially disrupting cell division at metaphase, thereby hindering the growth and spread of the glioblastoma cells.

What does the future hold for the Nativis Voyager® device in cancer treatment?

The Nativis Voyager® device shows promise in treating recurrent glioblastoma (rGBM) and could potentially extend its application to other tumor types and non-oncological applications. Ongoing research aims to explore integrating the Voyager into multi-modality treatment approaches, combining it with cognates and drug therapies. This integration could enhance the effectiveness of treatments and improve patient outcomes, offering a broader scope of application and more comprehensive treatment strategies in the future.